2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169751
    Dihydro-N-caffeoyltyramine 501939-19-1 98%
    Dihydro-N-caffeoyltyramine is a new phenolic amide that can be isolated from the root bark of wolfberry and has strong antioxidant activity and antifungal effects. Dihydro-N-caffeoyltyramine downregulates the expression of cyclooxygenase-2 by inhibiting the activity of C/EBP and AP-1 transcription factors.
    Dihydro-N-caffeoyltyramine
  • HY-169819
    Calcium influx inducer compound 634 882291-37-4 98%
    Calcium influx inducer compound 634 is a calcium influx inducer. Calcium influx inducer compound 634 (10 µM) enhances the release of extracellular vesicles (EVs) from mouse bone marrow-derived dendritic cells (mBMDCs). Calcium influx inducer compound 634 (10 µM) also increases the levels of CD86 and CD80 on the surface of mBMDCs, an effect that can be blocked by the calcium release-activated calcium channel inhibitor YM-58483 (HY-100831).
    Calcium influx inducer compound 634
  • HY-169833
    BL 6341A 78441-84-6 98%
    BL 6341A is an antagonist for histamine H2 receptor with Ki of 3.5-4.4 nM, that inhibits histamine-induced acid secretion and cAMP formation. BL 6341A can be used in research of gastric acid secretion related diseases, such as gastric ulcer or gastroesophageal reflux.
    BL 6341A
  • HY-169863
    DC360 2324152-25-0 98%
    DC360 is a synthetic retinoid analogue of all-trans retinoic acid (ATRA) which induces RARβ expression. DC360 can be utilized in characterization of retinoid signalling pathways.
    DC360
  • HY-169913
    ERAP1 modulator-1 2766036-51-3 98%
    ERAP1 modulator-1 (Compound 1) is the modulator for endoplasmic reticulum aminopeptidase 1 (ERAP1) with IC50 < 250 nM.
    ERAP1 modulator-1
  • HY-169927
    Ferroptosis-IN-16 98%
    Ferroptosis-IN-16 (Compound 13l) is a specific inhibitor for ferroptosis with an EC50 of 0.7 nM and 0.9 nM in ES-2 cell and LX-2 cell. Ferroptosis-IN-16 ameliorates Acetaminophen (HY-66005)-induced acute liver injury in mouse model, and exhibits good metabolic stability in mouse liver microsomes.
    Ferroptosis-IN-16
  • HY-169936
    ERAP1-IN-3 98%
    ERAP1-IN-3 (compound 13) is a potent endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitor, with a pIC50 of 8.6. ERAP1-IN-3 has potential for the research of cancer immunotherapy and autoimmune disease.
    ERAP1-IN-3
  • HY-169940
    Fibrostat 98%
    Fibrostat (Compound 5n) is a selective HDAC6 inhibitor that exerts antifibrotic effects by inhibiting HDAC6 activity, with an IC50 value of 63 nM. It also exhibits good selectivity over HDAC1, HDAC3, HDAC5, HDAC8, HDAC10, and HDAC11. Fibrostat significantly downregulates fibrotic markers (fibronectin and collagen 1) in fibroblasts. Additionally, Fibrostat demonstrated no toxicity in rat-perfused heart and zebrafish larvae models. Fibrostat shows potential for research into fibrosis-related diseases.
    Fibrostat
  • HY-169952
    RORγt inverse agonist 33 98%
    RORγt inverse agonist 33 (compound (R)-D4) is an orally bioavailable and inverse agonists of RORγt, with the IC50 of 21 nM. RORγt inverse agonist 33 plays an important role in rheumatoid arthritis research.
    RORγt inverse agonist 33
  • HY-17003R
    Saquinavir mesylate (Standard) 149845-06-7 98%
    Saquinavir mesylate (Standard) (Ro 31-8959/003 (Standard)) is the analytical standard of Saquinavir mesylate (HY-17003). This product is intended for research and analytical applications. Saquinavir (Ro 31-8959) mesylate is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir mesylate also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir mesylate (Standard)
  • HY-17007S
    Saquinavir-d9 1356355-11-7 98%
    Saquinavir-d9 (Ro 31-8959-d9) is the deuterium labeled Saquinavir (HY-17007). Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir-d9
  • HY-170218
    NLRP3-IN-76 98%
    NLRP3-IN-76 is an orally active NLRP3 inhibitor. NLRP3-IN-76 inhibits the production of NO, and the mRNA levels of proinflammatory cytokines (iNOS, IL-6, IL-1β and TNFα). NLRP3-IN-76 shows anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome and NF-κB signaling pathway. NLRP3-IN-76 ameliorates DSS (HY-116282C)-induced colitis and can be used for research of inflammatory bowel diseases (IBD).
    NLRP3-IN-76
  • HY-17021S
    Esomeprazole-d3 sodium 98%
    Esomeprazole-d3 (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole-d3 sodium
  • HY-170227
    Autotaxin-IN-7 98%
    Autotaxin-IN-7 (45), a pyridine-2-carboxylic derivative, demonstrates subnanomolar ATX inhibition (IC50 = 0.086 nM), with a favorable heart safety profile (hERG > 30 μM) and minimal fibroblast toxicity. Autotaxin-IN-7 (45) suppresses the TGF-β/Smad signaling pathway, downregulating α-smooth muscle actin (α-SMA) and extracellular matrix components (ECM). Autotaxin-IN-7 (45) is used in the research for pulmonary fibrosis.
    Autotaxin-IN-7
  • HY-170228
    c-Kit-IN-9 98%
    Kit-IN-9 (Compound D9) is an inhibitor of c-Kit. c-Kit-IN-9 inhibits the inflammatory responses in J774A.1, RAW264.7, MPMs cells and lung tissues by blocking the activation of the NF-κB pathway induced by LPS (HY-D1056). Meanwhile, c-Kit-IN-9 exhibits good anti-inflammatory activities in acute lung injury and sepsis mouse models. c-Kit-IN-9 can be used in the research of acute lung injury and related inflammatory diseases.
    c-Kit-IN-9
  • HY-170232
    RIPK1-IN-29 98%
    RIPK1-IN-29 (Compound 22) is a RIPK1 inhibitor, with an IC50 of 6.9 nM. RIPK1-IN-29 exerts anti-necroptotic (Apoptosis) activity by inhibiting RIPK1. In a TNF-α-induced in vivo inflammation model, at a dose of 10 mg/kg, RIPK1-IN-29 can protect mice from hypothermia and death. RIPK1-IN-29 can be applied to the research field of inflammatory diseases.
    RIPK1-IN-29
  • HY-170233
    NLRP3-IN-75 98%
    NLRP3-IN-75 is an orally active NLRP3 inhibitor. NLRP3-IN-75 suppresses IL-1β secretion (IC50 = 23 nM). NLRP3-IN-75 selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 exhibits superior efficacy in acute peritonitis, diabetic kidney disease and IBD models.
    NLRP3-IN-75
  • HY-17028A
    (Rac)-Besifloxacin hydrochloride 1398566-43-2 98%
    (Rac)-Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. (Rac)-Besifloxacin Hydrochloride is a DNA gyrase and topoisomerase IV inhibitor. (Rac)-Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. (Rac)-Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research.
    (Rac)-Besifloxacin hydrochloride
  • HY-170314
    EA-89 98%
    EA-89 is a potent and selective BRD9 inhibitor with antitumor activity. EA-89 is a Ligand for Target Protein for PROTAC. EA-89 can be used to synthesize PROTAC QA-68 (HY-150797).
    EA-89
  • HY-170317
    EA-89-Succinic acid 98%
    EA-89-Succinic acid (Compound 26) is the active control of the target protein ligand EA-89 (HY-170314), which can be used for the synthesis of PROTAC .
    EA-89-Succinic acid
Cat. No. Product Name / Synonyms Application Reactivity